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Division of Transplantation, Department of Surgery, University of Alberta, CanadaThe development of calcineurin inhibitors (CNIs) led to marked outcomes of LTx have improved with advances in surgical proce-
improvements in patient and graft survival after liver transplan-
tation (LTx). We have been left, however, with a dependence on
immunosuppressive agents with nephrotoxicity, neurotoxicity,
adverse impacts on cardiac risk proﬁle, and risk for malignancy.
These challenges need to be met against a dominance of hepatitis
C virus (HCV) and hepatocellular carcinoma (HCC) as indications
for liver transplant. Unmet needs for immunosuppression (IS) in
LTx include:
(1) Effective drugs that avoid CNIs toxicities.
(2) Agents without adverse impact on HCV recurrence.
(3) Compounds that minimize risk of HCC recurrence.
New immunosuppressives will need to address the above
needs while supporting patient and graft survival equivalent to
those achievable with CNIs, ideally without important new toxic-
ities. Two new classes of agents are currently in advanced clinical
development: belatacept, and the mammalian target of rapamy-
cin inhibitors (m-TORi). This manuscript will review evidence for
a role for m-TORi in LTx in a range of clinical scenarios including
patients with CNI nephrotoxicity or neurotoxicity, patients at risk
of (or with) HCV recurrence, and patients at risk of HCC
recurrence.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Liver transplantation (LTx) has become a standard therapy for
end stage liver disease, including that due to hepatitis C cirrhosis
and non-resectable hepatocellular carcinoma (HCC). TheJournal of Hepatology 20
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inhibitors (CNIs). However, chronic kidney disease (CKD) caused
by CNIs, recurrence of hepatitis C in the transplanted liver, and
recurrence of HCC remain major problems after LTx. Renal insuf-
ﬁciency in LTx is associated with progression to end stage renal
disease and a decrease in patient and graft survival [1–3]. CNIs
have been associated with a dose-dependent increase in the
post-transplant risk of HCC recurrence [4]. Minimizing the neph-
rotoxicity and exploring for anti-tumor effect of immunosuppres-
sive regimens may help to reduce the number of patients
developing CKD and HCC recurrence after LTx.
Sirolimus (SRL) and everolimus (EVRL) inhibit mammalian
target of rapamycin (m-TOR). The m-TOR is an evolutionarily
conserved PI3-kinase family member that plays a key role in
integrating different biochemical and growth factor signals,
including amino acids, glucose, ATP, and insulin [5]. m-TOR inhib-
itors (m-TORi) continue to be explored as immunosuppressive
drugs in allogeneic transplantation and as novel anticancer agents.
In this review article, we will discuss the impact of m-TORi in LTx,
with speciﬁc reference to the important areas of kidney function,
hepatitis C recurrence, and HCC recurrence, and thereby explore
the rationale for selective use of m-TORi in liver transplantation.
The ﬁrst report on use of m-TORi in LTx achieved a modest
67% 1-year survival in 15 patients, 8 of whom had HCC [6]. Early
reports by McAlister, Chang, and Trotter supported the potential
for SRL-based immunosuppression to achieve outcomes equal to
CNI-based protocols [7–9]. After a report of the second interna-
tional multicenter trial of SRL in LTx, delivered at the American
Transplant Congress in 2002, documenting an increase in rate
of graft loss and death and a trend to an increase in HAT in the
SRL/Tac arm [10], the Food and Drug Administration (FDA) issued
a ‘‘black box’’ warning on use of SRL in LTx. As appropriate under
the ‘‘black box’’, subsequent studies with SRL have focused on
areas and patients where potential adverse impacts from SRL
were felt to be outweighed by likely beneﬁt. These include
patients with post-transplant nephrotoxicity or neurotoxicity,
and patients with hepatocellular carcinoma (HCC), where the
anti-tumor impact of m-TORi may prove beneﬁcial. Review of
outcomes with m-TORi in these areas of liver transplantation will
form the core of this review.Mammalian target of rapamycin (m-TOR) inhibitors
Rapamycin, also known in clinical usage as SRL, was isolated from
a soil sample obtained in Easter Island (Rapa Nui) and was11 vol. 55 j 1441–1451
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identiﬁed as a potent antifungal metabolite. This macrolide, pro-
duced by Streptomyces hygroscopicus, inhibited cell proliferation
and so produced antitumor and immunosuppressive activity
[11]. In 1999, SRL was FDA approved for prevention of kidney
allograft rejection [12]. Rapamycin and three analogs modiﬁed
at C43 to increase solubility and bioavailability have undergone
clinical evaluation. The addition of an ester, ether, or phospho-
nate group yield temsirolimus, EVRL, and deferolimus, respec-
tively. SRL and EVRL are mainly used as immunosuppressive
medications in transplantation and are the focus of this review
(Fig. 1).Fig. 1. Structures of sirolimus and everolimus.The m-TOR signaling pathway
TOR was identiﬁed in yeast followed by the discovery of the m-
TOR. m-TOR is a key signaling kinase that affects broad aspects
of cellular functions, including metabolism, growth, survival,
aging, synaptic plasticity, and memory. Rapamycin engages
FK506-binding protein 1A, 12 kDa (FKBP12); the complex
engages and inhibits TOR but not calcineurin, thereby blocking
cell cycle progression at the G1 to S phase, causing inhibition of
T cell proliferation [13].
As shown in Fig. 2, the m-TOR pathway is activated by a vari-
ety of different classes of stimulations. There are at least two dis-
tinct m-TOR complexes, m-TOR complex1 (m-TORC1) and m-TOR
complex2 (m-TORC2), that have distinct relationships both to
upstream and downstream effectors and to each other [14,15].
Signals from growth factors (insulin or IGF-1), various cytokines,
co-stimulatory signals, Toll-like receptor (TLR) ligands, cellular
energy levels, hypoxia, cellular stress and DNA damage deter-
mine m-TORC1 activity. These signals mediate their effects
through the tuberous sclerosis complex 1 (TSC1)-TSC2 complex,
which is the main negative regulator of m-TORC1. Activated
m-TORC1 promotes mRNA translation by stimulating S6 kinase
(S6K1) and inhibiting EIF4EBP1 (eukaryotic translation initiation
factor-binding protein 1). m-TORC2 is not inhibited directly by
rapamycin, although long-term rapamycin administration dis-
rupts its assembly in some cells. m-TORC2 regulates actin cyto-
skeletal dynamics through the small GTPase RAS homologue
(RHO) and protein kinase C (PKC).The m-TOR in immunity and mechanism of
immunosuppression
m-TORi: impact on innate immunity
In addition to the regulating effects of m-TOR in dividing cells, it
has been recently demonstrated that m-TOR affects the innate
immunity system [16]. Inhibition of m-TOR promotes pro-inﬂam-
matory cytokines such as IL-12 and IL-1b, inhibits the anti-
inﬂammatory cytokines such as IL-10, and boosts MHC antigen
presentation via autophagy in monocytes/macrophages and
dendritic cells. Moreover, m-TOR regulates type1 interferon
production and the expression of chemokine receptors and co-
stimulatory molecules [17]. m-TORi blocks progression from G1
to S phase in natural killer (NK) cells but does not affect inter-
feron-c production in primary NK cell lines; cytotoxicity assays
showed modestly decreased NK cell activity against the YAC-1
cell line [17]. In vivo study in a rat to hamster skin xenograft
model did not show signiﬁcant effects [17,18].1442 Journal of Hepatology 2011m-TORi: impact on adaptive immunity
Inhibition of innate immunity by m-TORi affects adaptive immu-
nity via co-stimulatory molecules and cytokine production.
m-TORi also marked thymic involution, which is associated with
decreased T cell output [17]. By blocking cell cycle progression
from G1 into S phase in IL-2 stimulated T cell lymphocytes
[18]; rapamycin potently decreases the proliferation of CD4+ T
cells, although it does not alter the proportion of CD4+ single
positive T cells that upregulate their expression of forkhead box
P3 (FOXP3) in the thymus [16,17]. Furthermore, m-TOR-deﬁcient
CD4+ T cells efﬁciently differentiate into FOXP3+ regulatory T cells
(Tregs) upon stimulation, compared to wild-type. Differentiation
into T-helper (Th) 1, Th2, or Th17 cells was severely inhibited in
m-TOR-deﬁcient CD4+ T cells even in the presence of appropriate
polarizing cytokines [19]. m-TORi may be permissive to induction
of Tregs in organ transplantation [19], another potential mecha-
nism for immune suppression. Detail of T cell mechanisms regu-
lated by m-TOR have been reviewed [21].Pharmacology of m-TORi
The half-life of SRL and EVRL is approximately 60 h and 30–40 h,
respectively, and EVRL has a more rapid time to steady state
(4 days versus 6 days for SRL) [20,21]. Both compounds are
cleared through the liver via the hepatic cytochrome P450-3A4
microsomal system, which is the same metabolic pathway used
by cyclosporine and tacrolimus (Tac). Drugs which inhibit or
compete with the activity of cytochrome P450 systemmay signif-
icantly impair the clearance of both SRL and EVRL and lead to sig-
niﬁcant increase in systemic levels. Common drugs that may
cause clinically signiﬁcant elevations in blood concentrations
through inhibition of metabolism include ﬂuconazole, azithromy-
cin, and protease inhibitors.Clinical experience with m-TORi: adverse events and risks
A rationale for selective substitution of m-TORi for CNIs in LTx
depends on evidence for effective immune suppression and avol. 55 j 1441–1451
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Fig. 2. An overview of the m-TOR signaling pathway and relative activities.
JOURNAL OF HEPATOLOGYfavorable balance in toxicities. After the black box warning of
2002, the FDA, in 2009, notiﬁed health care professionals of pre-
liminary data suggesting increased mortality in stable liver trans-
plant patients after conversion from CNIs to SRL.
A retrospective review of SRL-associated adverse events in
175 patients demonstrated bilateral leg edema (57.1%), dyslipide-
mia (44%), dermatitis (25.3%), oral ulcers (24.2%), joint pain (23%),
pleural effusion (16.5%), increased abdominal girth (5.5%), gen-
eral edema (5.5%), pericardial effusion (5.5%), facial edema
(2.2%), and upper extremity edema (1.3%) [22]. Asrani published
a systematic review and meta-analysis of SRL in LTx patients with
renal insufﬁciency [23]. The relative risk ratios of death
(RR = 1.12), graft failure (RR = 0.8), and rejection (RR = 0.88) were
not signiﬁcantly increased at 1 year after SRL initiation. Protein-
uria and poor wound healing were similar in both groups. SRL
was associated with a trend to a higher risk ratio (not statistically
signiﬁcant) of renal replacement therapy (RR = 1.71) and need for
statin therapy (RR = 2.93) as well as a signiﬁcantly higher risk of
infection (RR = 2.47), rash, edema (RR = 2.49), and oromucosal
ulcers (RR = 7.44). Discontinuation due to intolerance was signif-
icant in the SRL arm (33–55%, RR = 3.61). Neff reportedJournal of Hepatology 2011SRL-related, biopsy conﬁrmed hepatotoxicity requiring discontin-
uation in 2 out of 10 LTx patients switched for renal insufﬁciency
(n = 6) or chronic rejection [24]. SRL-related acute hepatitis was
also reported in a renal transplant recipient [25]. Similar adverse
events have been observed with EVRL vs. cyclosporine A (CsA)
monotherapy. A 78 patient study demonstrated higher choles-
terol and a trend to more incisional hernias [26], while a 145
patient study demonstrated higher rash (6.9%), cholesterol
(13.9%) and mouth ulceration (26.4%) [27].
A multicenter retrospective analysis in 240 LTx patients
demonstrated similar adverse effects with EVRL [28]. Mean
white blood count decreased signiﬁcantly and total cholesterol
and triglyceride levels increased signiﬁcantly. The principal
adverse event was dyslipidemia, which was controlled by
reducing the dose and adding a statin in LTx with SRL or EVRL
[29].
Adverse effects of m-TORi are frequent and may be important.
This m-TORi toxicity proﬁle supports CNI as the agents of ﬁrst
choice post liver transplantation. While successful clinical appli-
cation requires experience and careful observation, m-TORi may
be an acceptable immunosuppressive alternative in LTx patientsvol. 55 j 1441–1451 1443
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intolerant of CNIs, or in clinical scenarios with the potential for
speciﬁc beneﬁts from m-TORi.Potential clinical advantages of m-TORi: nephrotoxicity
CNIs have been implicated as a principal cause of post-transplant
renal dysfunction. Non-renal solid-organ transplant recipients
have a shorter lifespan than the general population, and their sur-
vival is further compromised when chronic kidney disease (CKD)
develops [30]. Ojo et al. reported that the relative risk of death
after development of CKD in non-renal organ recipients was
4.55 [2]. While present even before the need for dialysis, it was
highest for recipients on dialysis [31–33]. CNIs induce reversible
vasoconstriction of afferent and efferent glomerular arterioles.
Renal hemodynamic studies in CsA-treated patients have
revealed decreased glomerular ﬁltration rate (GFR), elevated
mean arterial pressure, increasing renal vascular resistance, and
increased albumin excretion. With chronic use, these perturba-
tions result in progressive arteriolopathy and glomerular ische-
mic collapse. Hyperﬁltration injury occurs in remaining
nephrons, sometimes leading to end stage renal disease [34].
Renal biopsy studies among nonrenal organ transplant recipients
with CKD showed interstitial ﬁbrosis with a ‘‘striped’’ appear-
ance, nodular arteriolar hyalinosis, and later, tubular atrophy
with glomerulosclerosis and arteriosclerosis [2,35–37]. m-TORi
may have a role in minimizing post-transplant CKD; a critical
look at m-TORi impact on renal function is required. The pub-
lished impact of m-TORi on renal function has been variable,
including proteinuria with de novo SRL [38], while less data is
available about EVRL [39]. Results from animal experiments
[40,41] and clinical studies [42–45] suggest that pre-existing
chronic nephropathy or renal impairment might increase the risk
of adverse effects from SRL and that inhibition of vascular endo-
thelial growth factor (VEGF) is important for these effects. To gain
a better focus on the relative renal toxicity risks from CNI and
m-TORi, we next review renal function outcomes in clinical trials
with m-TORi in LTx.Clinical trials of m-TORi in LTx patients with renal
insufﬁciency
De novo clinical studies of m-TORi in LTx
A placebo-controlled trial randomized 119 patients to EVRL at
0 mg/day, 1 mg/day, 2 mg/day, or 4 mg/day, all with prednisone
and oral CsA (trough 150–400 ng/ml) [46]. Creatinine and creat-
inine clearance remained stable to 36 months, while cholesterol
and triglyceride increased in all groups. No differences were
observed in creatinine clearance and acute rejection, thrombocy-
topenia or leucopenia, although patients taking 2 mg/day or
4 mg/day EVRL had the lowest numerical rate of rejection. This
study demonstrated that EVRL in combination with CsA in de
novo liver transplant recipients had an acceptable safety and tol-
erability proﬁle and was associated with a lower rejection rate
(not statistically signiﬁcant) in comparison with CsA combined
with placebo. No evidence for beneﬁt to renal function was seen.
Animal studies demonstrated a risk of increased nephrotoxicity
with CsA/m-TORi combination therapy [47,48], consistent with
the results from renal transplantation with combination of CsA1444 Journal of Hepatology 2011and SRL [49]. Therefore, it is important to investigate use of de
novo m-TORi without CNIs in liver transplantation. The course
of renal function in de novo liver transplantation recipients with
EVRL therapy has been evaluated in an open-label, randomized
multicenter phase III study (Clinical Trials.gov Identiﬁer
NCT00378014), although results are not yet available (http://clin-
icaltrials.gov/show/NCT00378014).Clinical studies of CNI conversion to m-TORi in LTx
An important question is whether CNIs can be stopped and
patients switched to m-TORi to avoid CNI-related CKD. Morard
switched 48 patients to SRL a median of 19.4 months after LTx
for reasons of renal impairment (78%), CNI-neurotoxicity (13%),
or post-transplant cancer (9%) [50]. Nineteen percent presented
severe (cGFR 20–40 ml/min) and 45% moderate (40–70 ml/min)
renal impairment at switch. Mean cGFR improved from 33 to
48 ml/min in patients with severe and from 56 to 74 ml/min in
patients with moderate renal impairment. Patients with a
cGFR >70 ml/min did not beneﬁt. Acute rejection occurred in 8
patients (17%) with a mean delay of 4 months; 5 out of 8 patients
improved after increasing SRL trough levels to 10–15 lg/L. The
authors concluded that conversion from CNI to SRL is safe and
is associated with signiﬁcant renal function (cGFR) improvement,
but warned that SRL may worsen nephropathy (some developed
severe albuminuria >500 mg/L) if patients have severe hyperten-
sion and pre-existing albuminuria. Preconversion albuminuria
(>30 mg/L) and high SRL trough levels (>9.5 lg/L) were signiﬁ-
cant risk factors for SRL treatment withdrawal. Recently, a multi-
center study of 240 patients converted to EVRL a mean of
4.9 years after liver transplant was e-published [51]. In the com-
plete cohort, estimated GFR improved from 64.2 ml/min at day 0
to 68.4 ml/min at month 12 after LTx; no control group (CNIs
alone) was included in this study. Patients with baseline serum
creatinine >130 lmol/L had an improvement in eGFR from
44.3 ± 15.7 ml/min to 53.7 ± 26.0 ml/min after 12 months
(p = 0.003). Over 60% of patients were maintained free of CNIs
at 12 months with a rate of biopsy proven acute rejection of only
1.6% (4 patients) and an acceptable safety proﬁle.
Several groups have reported that signiﬁcant improvement of
renal function was observed in patients with shorter times
between LTx and conversion to m-TORi from CNI [52,53]. Two
small prospective randomized, single center trials demonstrated
that CNI withdrawal was associated with a signiﬁcant improve-
ment in creatinine clearance at 3 months, but that this improve-
ment was no longer statistically signiﬁcant at 12 months [54,55].
Watson showed improvement in creatinine clearance at
3 months on SRL (75 ml/min) compared to control (56 ml/min)
(p = 0.012), with a trend at 12 months (72 ml/min vs. 58 ml/
min; p = 0.09). In a recent multicenter randomized EVRL conver-
sion study, 145 LTx patients at mean >3 years post-transplant
with CNI reduction (38%) or discontinuation (62%) showed stable
(but not improved) renal function at 6 and 12 months (Fig. 3)
with no difference in graft loss or acute rejection [27], again sug-
gesting that conversion several years after transplant may be too
late to show beneﬁt.
A prospective trial of early (4 week) conversion in 40 LTx recip-
ients demonstrated that 57% of subjects improved creatinine
clearance by conversion from CNIs to EVRL-monotherapy [56]. A
second early (30 day) conversion study that was a 12-month, pro-
spective, randomized, single center, open-label, parallel-groupvol. 55 j 1441–1451
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EVRL monotherapy in LTx in 78 patients (EVRL n = 52, CsA
n = 26) [26]. All patients were treated with CsA for the ﬁrst
10 days, then received EVRL in combination with CsA up to day
30, then were either continued on EVRL-monotherapy or main-
tained on CsAwith/withoutmycophenolatemofetil (MMF) in case
of chronic kidney disease. Signiﬁcant improvement of GFR was
observed at 1, 2, 3, 6, and 12 months after conversion (Fig. 4). Early
post transplant CNI-free immunosuppression with EVRL-mono-
therapy in de novo LTx recipients was found to be associated with
a signiﬁcant improvement in renal function, with similar inci-
dences of rejection and major complications. Results from a
recently published large SRL conversion study in renal transplan-
tation revealed similar outcomes. Of 830 renal allograft recipients
6–120 months post-transplant, 555 were converted to SRL while
275 were maintained on CNI (Tac or CsA). While no signiﬁcant
difference was seen in patients with GFR <40 ml/min at baseline,
on-therapy analysis in the 743 patients within the GFR >40
ml/min stratum revealed signiﬁcantly higher GFR at 12 and
24 months in the SRL conversion group (66.2 vs. 60.1 ml/min,
p = 0.004 and 63.8 vs. 59.0 ml/min, p = 0.049) [57]. While the liter-
ature is not homogeneous, the balance of results supports a mod-
est beneﬁt in renal function post-LTx when CNIs are switched to
m-TORi early and with use of moderate SRL/EVRL trough levels.
The data suggest less beneﬁt in patients with severe renal dys-
function or even of adverse impact post conversion in patients
with preconversion albuminuria (>30 mg/L).m-TORi in CNI-induced neurotoxicity after LTx
Neurotoxicity is a relatively common and potentially serious
adverse effect of CNIs [58] that occurs in about 25% of patients
after LTx. Both CsA and Tac may produce a spectrum of neurolog-
ical impact that varies from relatively mild tremor and acute con-Journal of Hepatology 2011fusional state to headache, seizures, status epilepticus, and major
speech or language abnormalities that at its most severe may be
associated with central pontine myelinolysis (CPM) [59–62].
Neurotoxicity correlates poorly with trough levels. The impact
of concomitant electrolyte abnormalities may be important,
including the association of hypomagnesemia with seizures and
rapid rises in serum sodium with CPM. Appropriate response
may vary from dose reduction or switching from Tac to CsA for
mild toxicity, to immediate cessation of any CNI for life threaten-
ing neurotoxicity. Switch from Tac to CsA has been associated
with rates of acute rejection up to 30% [63]. A 202 patient study
demonstrated that SRL use was not associated with neurotoxicity
in kidney or liver recipients [64], nor in heart transplantation
[65]; suggesting that a switch from CNIs to m-TORi is another
option for CNI related neurotoxicity. Vivarelli et al. reported 3
LTx patients that were switched to SRL because of Tac-related
neurotoxicity with improvement of a severe speech disorder in
one case and encephalopathy in the other two [66]. A conversion
study also demonstrated that 6 LTx patients (13%) were switched
from CNIs to SRL due to neurotoxicity; symptoms such as head-
ache and tremor completely disappeared after the switch [50],
chronic partial epileptic crisis did not relapse. Another study
reported on 3 LTx patients (7.5% of trial total) that were switched
from CNIs to EVRL with recovery from peripheral neuropathy in 2
but persistence of headache in the third [56].
Switching from CNIs to m-TORi appears a safe and effective
strategy for consideration in patients who develop CNI-related
neurotoxicity.The impact of sirolimus on the clinical course of recurrent
hepatitis C (HCV) after LTx
Graft and patient survival after LTx have improved for all
indications except HCV-related cirrhosis, where they continue
to be 10–15% lower than non-HCV controls [67]. HCV re-infection
usually occurs immediately after LTx with a rapid increase in
HCV-RNA peaking at 1–3 months; acute lobular hepatitis devel-
oping in 60–80% of patients at a median of 4–6 months andvol. 55 j 1441–1451 1445
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cirrhosis in 20% by 5 years [68,69]. Progression of HCV disease to
cirrhosis is affected by several variables: notably high levels of
pre-transplant viremia, donor variables (age, steatosis, ische-
mic/preservation injury), human immunodeﬁciency virus/cyto-
megalovirus co-infection, higher levels of immunosuppression
(pulse steroids or T cell depleting antibody use – OKT3 or thymo-
globulin), abrupt modiﬁcations of immune status, and post-LTx
diabetes [69,70].
Optimization of immunosuppression is a key in managing
recurrent HCV disease. Data regarding the effect of different
immunosuppressive agents on HCV replication and/or progres-
sion of liver disease is controversial [71]. CNIs exert different
in vitro and in vivo effects on HCV disease. While CsA has a clear
in vitro antiviral effect in the subgenomic HCV replicon system
[72–74], there is little evidence that clinical disease progression,
measured by RNA levels or the necroinﬂammatory score, is differ-
ent between patients on CsA vs. Tac [72,75,76].
Laboratory evidence suggests that m-TORi may affect HCV
disease progression by altering the rate of HCV replication or
by inﬂuencing the necroinﬂammatory effects of infection on the
allograft. SRL has been reported to have potent anti-ﬁbrotic prop-
erties in rat models of cirrhosis with signiﬁcant inhibitory effects
on procollagen-alpha 1 and transforming growth factor-beta 1.
Decreased activity and ﬁbrosis progression have been reported
in patients with recurrent HCV disease [77].
Laboratory evidence for the role of m-TORi on HCV progres-
sion is mixed. Cell culture experiments using an Huh7 replicon
cell line demonstrate that infected cells are resistant to apoptosis,
and stimulation of the pro-survival PI3K-Akt pathway and m-TOR
by HCV not only protects cells against apoptosis but may also
contribute to the maintenance of steady-state levels of HCV rep-
lication [78]. Biochemically, the NS5A protein has been found to
enhance HCV virus replication through p70S6K phosphopeptide
[79]. SRL inhibits the m-TOR/p70S6K pathway and may reduce
in vivo phosphorylation of NS5A phosphopeptides and therefore
viral replication. This effect, however, may be dose dependent.
Studies of non genotype-1 virus in cell culture which used higher
doses of rapamycin (100 nM) have shown that m-TORi may
increase the production of HCV core protein by inhibiting, the
suppressor of cytokine signalling 3 (SOCS3) [80,81].
Clear clinical data on the effect of SRL on HCV recurrence
remains scarce. In contrast to early, unpublished reports that
SRL may worsen biochemical outcomes in recurrent HCV [82],
Wagner et al. reported lower viral RNA levels, slower ﬁbrosis pro-
gression, and higher survival in the 39 SRL treated patients from a
group of 67 patients with post-LTx HCV recurrence [83]. We
found the use of SRL in an HCV-positive cohort did not affect tim-
ing of recurrence, but markedly slowed the progression of the
disease on serial biopsy [84]. Similar ﬁndings have been reported
in other series. Mckenna et al. reported a decrease in RNA levels
as well as reversal of established ﬁbrosis on serial protocol liver
biopsies in HCV-positive LTx recipients after SRL conversion
[85]. Preliminary data from our own center suggests that SRL
based immunosuppression is associated with improved response
rates to anti-HCV treatment after LTx [86].
The published evidence is mixed in respect to the impact of
m-TORi on HCV. The central role of m-TOR in a host of cellular
signalling pathways has resulted in suggesting potential beneﬁ-
cial and adverse impacts when different intracellular signaling
cascades have been examined. Intriguingly, some of the variation
in the literature appears to support dose-dependent variable1446 Journal of Hepatology 2011effects of SRL on HCV proliferation. Clinical evidence is develop-
ing for a beneﬁcial role of m-TORi on slowing the progression
of HCV disease after recurrence and possibly in enhancing SVR
rates. At minimum, we note little evidence for adverse impact
of m-TORi therapy on HCV disease post-LTx.m-TOR inhibitors in LTx for hepatocellular carcinoma (HCC)
Immunosuppression after LTx for HCC must achieve safe control
of the immune response. Can it, in parallel, achieve a reduction in
tumor recurrence (improved tumor-free survival), and so
improved overall survival? We will explore these two questions
sequentially in the next section. Control of alloimmunity in LTx
does not mandate an extremely low rate of rejection, but requires
a manageable rate and severity of acute rejection, with an
absence of graft loss due to rejection whether acute or chronic.
We reported a sequential series of 40 patients with HCC (21
beyond Milan criteria) transplanted between 1996 and 2003 on
SRL based therapy post-transplant [87]. Eligibility criteria
included single tumors to 7.5 cm, and multiple tumors (no limit
by number) up to 5 cm. At mean 44 months follow-up, 5 tumors
(12.5%) had recurred, with 81% of within Milan and 77% of
extended criteria patients alive and free of HCC recurrence. We
updated our experience to a sequential series of 70 consecutive
HCC patients transplanted to 2007 with 49 months median fol-
low-up [88]. Eight tumors had recurred, 2 out of 34 (6%) within
Milan criteria, and 6 out of 36 (17%) in the extended criteria
group. Four-year tumor free survivals were 73% (Milan) and
75% (beyond Milan). Acute rejection was seen in 52% of patients
with this protocol of aggressive reduction of immunosuppression
targeting SRL-monotherapy, but no grafts were lost to acute or
chronic rejection. No patient experienced hepatic artery throm-
bosis. Infection related mortality was 3%. SRL was continued in
88% of patients at 1 year and in 80% at 4 years, while 70% of
patients were on the protocol planned SRL-monotherapy at
4 years. These papers support the ability of SRL based immuno-
suppressive protocols to safely control the alloimmune response
and to achieve outcomes equal to CNI based regimens, while
achieving survival outcomes acceptable to most centers with
patients whose tumor burden are both within and signiﬁcantly
beyond the Milan criteria. While encouraging, such uncontrolled
series cannot establish an effective anti-tumor impact of m-TORi
on HCC. To date, no adequately powered randomized clinical tri-
als of m-TORi immunosuppression in HCC have been reported.
Nevertheless, a wealth of evidence is available from in vitro
experiments, in vivo animal studies, and clinical experience to
support further prospective randomized trials of replacement of
standard CNI/steroid immunosuppression with m-TORi in
patients with HCC. These bodies of published evidence on the
impact of both CNI and m-TORi on HCC will now be reviewed.
Hojo et al. reported CsA inducing an invasive phenotype in
adenocarcinoma cells in vitro and leading to increased tumor
growth and metastasis by a TGF-beta associated mechanism
independent of recipient immune cells [89].
Following liver transplant in rats with HCC, Freise docu-
mented that CsA treatment was associated with survival reduc-
tion from 47% to 18% at 100 days in parallel with increased
numbers of metastases [90].
Early clinical reports of adverse impact of CNI immunosup-
pression on HCC included a dramatic reduction in tumor doublingvol. 55 j 1441–1451
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time from 274 to 44 days when comparing HCC recurrences after
liver resection to those after liver transplant with CsA [91], and
higher recurrence rates in patients maintained on steroid long
term [92]. Additional evidence of an adverse impact of CNI on
HCC is provided by Vivarelli’s report of 70 HCC patients on CsA
based immunosuppression with a 10% recurrence rate. Multivar-
iate analysis revealed the sole independent predictor of recur-
rence was blood CsA level (p = 0.001) [93]. In vitro reports of
SRL impact on tumor cell lines included Schumacher’s paper
where SRL inhibited while Tac stimulated in vitro growth of hep-
atoma cell lines [94]. Guba et al. demonstrated that SRL inhibited
tumor growth by an anti-angiogenic mechanism that involved
blockage of VEGF signalling to endothelial cells [95]. A subse-
quent report by Guba demonstrated that SRL induced extensive
local microthrombosis of mouse tumor tissue vasculature via tis-
sue factor in the presence of VEGF, without such an impact on
adjacent non-tumor tissues [96]. Intravital microscopy of tumors
implanted in a dorsal skinfold chamber showed dramatic
decrease in tumor vascularity after 3 days treatment with rapa-
mycin at 1.5 mg/kg/day. Tumor speciﬁc thrombosis was docu-
mented in both orthotopically implanted pancreatic tumors and
heterotopically implanted colon carcinomas (mimicking primary
and metastatic tumors, respectively). The central role of m-TOR
as a regulator of nutrient uptake (impact on amino acid and glu-
cose transporters), cell growth and proliferation, and angiogene-
sis has been reviewed [15,97,98,101].Does the beneﬁcial impact of m-TORi on cancer in the lab
translate to the clinic?
Clinical research supporting a beneﬁcial impact of m-TORi in
malignancy includes studies reporting skin cancers, total malig-
nancies and HCC outcomes in renal and liver transplant popula-
tions. Stallone et al. documented complete remission of
cutaneous Kaposi’s sarcoma in 15 out of 15 renal transplant
recipients after 3 months therapy with SRL (and CNI discontinu-
ation) [99]. Kaufmann et al. reported use of m-TORi was associ-
ated with reduction in overall rate of new onset post-transplant
malignancy (NOPTM) [100]. In a review of 33, 249 patients from
the Scientiﬁc Registry of Transplant Recipients (SRTR), 30,424 CNI
treated patients had an incidence of NOPTM of 1.81% within
963 days of transplant, and a 1.00% incidence of de novo non-skin
solid malignancies. Of 504 SRL treated patients (in the absence of
CNI), 3 (0.60%) developed NOPTM and none developed de novo
non-skin solid malignancies. Patients treated with SRL in combi-
nation with CNI had an intermediate risk (0.47% de novo non-skin
solid malignancies and 0.60% NOPTM). Similar outcomes with
reduced rates of skin cancers as well as total malignancies were
reported by Schena et al. in a series of 830 renal allograft recipi-
ents 6–120 months post-transplant who were randomized to
continue CNI (n = 275), or switch to SRL (n = 555). At 24 months,
total malignancies were 21 (3.8%) in the SRL conversion group
and 30 (11.0%) in the CNI continuation group (p <0.001) while
skin cancers totalled 12 (2.2%) vs. 21 (7.7%), respectively
(p <0.001) [57]. Salgo et al. recently reported a prospective, single
center trial of 44 recipients a mean of 229.5 months after kidney
transplant who had developed skin lesions and were randomized
to a switch to SRL/prednisone or continuation of baseline immu-
nosuppression (predominantly azathioprine/prednisone) [101].
The stop of progression or regression of premalignant lesionsJournal of Hepatology 2011was signiﬁcantly superior in the SRL group at 6 months
(p <0.0005) with an increased impact at 12 months (p <0.0001)
Assessment by the single treatment-blinded dermatologist
(including skin biopsy as indicated) also reported only one non-
melanoma skin cancer (NMSC) in the SRL treated patients within
the next year and 8 NMSC in the control group (p = 0.0176). SRL-
based immunosuppression was able to delay or induce regression
of premalignant lesions and to decelerate the incidence of new
NMSC in renal transplant recipients even when instituted many
years after transplantation.
Several reports of association of m-TORi with improved out-
comes in HCC patients in the clinic have also been published. Els-
harkawi et al. reported 3 patients with pulmonary metastases
from HCC who achieved complete remission for 18 months after
SRL was substituted for CNI [102]. Zimmerman et al. reported 97
patients transplanted for HCC: 45 received SRL and low dose CNI
while 52 were treated with CNI alone. SRL was administered to
all tumor patients in the ﬁrst 3 years of the series (2000–2002)
and to those with creatinine levels above 1.5 mg/dl thereafter.
Overall, 12 patients (12.4%) experienced HCC recurrence and
there were 10 HCC related deaths. Post-transplant therapy with
SRL and low dose CNI was associated with a signiﬁcantly lower
rate of HCC recurrence (6.7% vs. 17.3%) and an increased rate of
recurrence free survival (79% vs. 54%) than standard CNI treat-
ment [103]. While all 3 SRL recurrences occurred in stage 3 cases,
3 out of 9 recurrences in the CNI group occurred in patients with
early stage disease. Zhou et al. [104] reported data on 73 HCC
patients from Shanghai. In patients beyond Milan criteria, 27
patients on SRL therapy achieved higher overall 2 year survival
than 46 on Tac (80% vs. 59%, p = 0.001). Both studies were uncon-
trolled, retrospective, single center analyses. Vivarelli et al.
reported 2 groups of 31 patients matched for year of transplant,
tumor histology, and alpha fetoprotein (AFP). SRL was adminis-
tered to patients who demonstrated unfavorable prognostic fac-
tors for tumor recurrence or had renal or neurological
dysfunction. Despite the unfavorable tumor and survival charac-
teristics, those patients on SRL and low dose Tac (mean 4.6 ng/
ml) achieved a >20% survival advantage at 2 years (85% vs. 64%,
p = 0.0001) over patients on Tac only (mean level 8.5 ng/ml)
[105].
Chinnakotla et al. [106] reported a case-control study of 227
patients transplanted for HCC (1995–2006) and within Milan cri-
teria on imaging. SRL was the preferred immunosuppression for
HCC patients subsequent to 2000. Analysis revealed no differ-
ences between SRL treated and Tac/MMF treated patient groups
for tumor size, number of nodules, proportion within Milan crite-
ria, vascular invasion, tumor grade, Metroticket-estimated 5-year
survival (for those beyond Milan criteria), or tumor prognostic
score. While 121 SRL treated patients had a 5-year Metroticket
predicted score of 52.9%, and 106 Tac/MMF patients had a pre-
dicted 52.3% survival, Kaplan–Meier actual survivals for 5 years
were 80% and 59%, respectively (p = 0.0001). Only 4 SRL treated
patients (3.3%) died due to tumor recurrence, while 19 (17.9%)
Tac/MMF treated patients succumbed for this reason. While the
preference for SRL in the group transplanted after 2000 could bias
survival toward this cohort, most (14.6%) of the 21% survival
advantage was directly due to a lower incidence of death due
to HCC recurrence, not an era sensitive factor.
We recently reported analysis of 2491 patients from the SRTR
transplanted for HCC (2002–2009) and continued on stable
immunosuppression for a minimum of 6 months after hospitalvol. 55 j 1441–1451 1447
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discharge [107]. Given UNOS guidelines on adherence to Milan
criteria in the USA, the cohorts for analysis on differing immuno-
suppressive agents were remarkably homogenous with only 0.2%
beyond a total tumor volume of 115 cm3, and only 6% with serum
AFP above 400 ng/ml, two factors we have reported to predict
tumor recurrence in the SRTR dataset. Univariate analysis of
immunosuppressive treatment inclusive of on vs. off Tac, CsA,
SRL, MMF, steroids, anti-CD25 antibody induction therapy, or
thymoglobulin induction therapy revealed a survival advantage
of 6.4% at 3 years and 14.4% at 5 years for 109 patients treated
with ongoing SRL for >6 months (p <0.05) when compared to
2382 patients on non-SRL immunosuppression. Anti-CD25 anti-
body induction therapy had a smaller (6% at 5 years) but signiﬁ-
cant survival advantage as well.
In order to clarify if the beneﬁts were speciﬁc to HCC patients,
we next analyzed 12,167 non HCC SRTR patients from the same
time span. While the requirement for a minimum 6 months of
stable immunosuppression excluded 25,201 of a total 39,859
patients from the analysis, we believe this qualiﬁcation for inclu-
sion in the analysis strengthens the validity of the interpretation.
In the non-tumor cohort, anti-CD25 antibody therapy was not
associated with any difference in outcomes, while SRL treated
patients demonstrated a slight trend to poorer outcomes (3.3%
at 5 years, p = 0.14). On multivariate Cox analysis (corrected for
MELD, year of transplant, primary non-HCC liver disease, age at
transplant, and when applicable for total tumor volume, AFP,
and pre-transplant HCC treatment) independent predictors of
survival in HCC patients were: SRL therapy (hazard ratio 0.53,
95% conﬁdence intervals 0.31–0.92, p <0.05), induction therapy
with anti-CD 25 antibody (HR 0.64, CI 0.45–0.90, p <0.01), and
in non-HCC patients: CsA therapy (HR 1.3, 95% CI 1.0–1.7,
p <0.05). The beneﬁt of SRL therapy in the HCC patient group
was not seen in the non-tumor patients, strongly supporting a
speciﬁc beneﬁt of SRL for patients with HCC. Of interest, Tac ther-
apy was associated with a 6.1% survival advantage at 5 years in
the non-tumor patients (p 60.001), but demonstrated no advan-
tage in the HCC patient group.Conclusions
CNIs have been documented to have adverse impact on cancer in
in vitro and in vivo animal studies and to have dose related
adverse impact on HCC recurrence and survival in clinical series.
m-TORi have demonstrated multiple mechanisms of anti-tumor
activity in vitro including angiogenesis inhibition associated with
reduced VEGF, proliferation inhibition associated with reduced
TGF beta, and tumor speciﬁc microvascular thrombosis associ-
ated with increased tissue factor production. SRL has been asso-
ciated with a reduction in HCC recurrence and improved overall
and tumor free survival in several single center retrospective
reviews of HCC patients undergoing LTx. An SRTR database
review has demonstrated a 14.4% survival advantage at 5 years
for HCC patients receiving SRL based immunosuppression. While
to date, no reports of adequately powered and controlled pro-
spective studies have been published or presented, we believe
the outcomes reviewed above justify expanded exploration of
m-TORi in HCC patients undergoing LTx and are strong impetus
for further active study in this area. Outcomes of an ongoing
international multicenter trial of SRL vs. non-SRL containing1448 Journal of Hepatology 2011immunosuppressive protocols in patients with HCC (the SiLVER
study) are anticipated [108].
An ongoing phase III study of EVRL in LTx will also analyze
impact in the subset of patients with HCC and so will add addi-
tional valuable insights to this important question – do m-TORi
beneﬁt patients undergoing liver transplantation for HCC?How might m-TORi help meet unmet needs in
immunosuppression for liver transplantation?
m-TORi are capable of replacing CNIs in patients with nephrotox-
icity, with potential for signiﬁcant improvement in renal func-
tion. Results appear to be best with early conversion; beneﬁts
may be limited when patients have advanced renal dysfunction;
in patients with signiﬁcant proteinuria, aggravation of renal dys-
function may occur. m-TORi appear as an acceptable immuno-
suppressive alternative when neurotoxicity is a signiﬁcant
post-transplant challenge.
There is as yet no clear message on the impact of m-TORi in
HCV infected liver transplant patients. In vitro and clinical data
reporting impact on replication is mixed. Preliminary data sup-
ports slower progression of disease (especially ﬁbrosis) and
includes a suggestion of improved SVR rates.
There exists a substantial body of in vitro data and in vivo ani-
mal data on beneﬁcial impact of m-TORi (and adverse impact of
CNIs) on rates of cancer development and metastasis, inclusive of
detailed mechanistic studies. In vitro and animal data with HCC
models is limited. A growing body of clinical evidence supports
SRL based immunosuppression and/or reduction of CNI to be
associated with decreased rates of new cancer development
and suggests beneﬁt for patients transplanted for HCC. Prospec-
tive randomized clinical trials addressing m-TORi immunosup-
pression in liver transplantation for HCC are ongoing.Conﬂict of interest
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